预测心脏骤停后的生存时间:一项观察性队列研究
Ian R Drennan1,2,3, Kevin E Thorpe4, Damon Scales5
1Department of Emergency Services, Sunnybrook Health Science Centre, Toronto, ON, Canada.
Resuscitation plus
|September 4, 2023
概括
一种新的临床预测模型准确地分类了在停心后早期的医院外心脏骤停 (OHCA) 后的成年患者的风险分层. 这种工具有助于早期预测患者的结果,改善心脏骤停后的护理策略.
科学领域:
- 紧急医疗 紧急医疗
- 心脏病学 心脏病学
- 临床预测模型临床预测模型
背景情况:
- 在北美,每年发生超过40万例非医院心脏骤停 (OHCA),其存活率低于10%至出院.
- 心脏骤停后患者的结果受到众多因素的影响,需要有效的预后.
- 目前的预后通常建议在自发循环 (ROSC) 恢复后72小时进行,这可能会推迟关键的管理决策.
研究的目的:
- 开发和内部验证一种新的临床预测规则,用于心脏骤停后期患者的早期风险分层.
- 确定可以预测患者结果的因素,比ROSC后的标准72小时标志更早.
- 创建一个工具,以改善后OHCA护理的管理和资源配置.
主要方法:
- 在2010年至2015年期间,对3432名经历OHCA的成年患者进行了回顾性队列研究.
- 使用顺序逻辑回归来分析神经学结果 (修改的兰金尺度).
- 采用了对二元神经学结果和存活到医院出院的逻辑回归,并通过引导方法进行内部验证.
主要成果:
- 开发的临床预测模型在顺序尺度上显示了神经学结果的强大预测性能 (内部验证后AUC为0.89).
- 该模型在评估神经学结果作为二进制变量时保持了预测准确性.
- 该模型还在预测医院出院生存率方面表现强.
结论:
- 一个经过验证的临床预测模型可以准确地分层风险,分层成人心脏骤停患者早期心脏骤停后的风险.
- 这种模式为早期干预和量身定制的患者管理策略提供了潜力.
- 建议在不同的医疗保健机构进行外部验证,以获得更广泛的临床应用.
更多相关视频
相关概念视频
01:15Assumptions of Survival Analysis
153
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
153
01:20Actuarial Approach
96
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
96
01:20Comparing the Survival Analysis of Two or More Groups
222
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
222
01:21Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
01:18Introduction To Survival Analysis
276
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
276
01:09Censoring Survival Data
125
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
125